Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Kidney Fibrosis Treatment Market Revenue Outlook: What CAGR Lies Ahead Through 2030?
The kidney fibrosis treatment market size has demonstrated robust growth in recent years. It is anticipated to increase from $6.06 billion in 2025 to $6.54 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.0%. The growth observed in the past can be attributed to several factors including the rising prevalence of chronic kidney disease, the limited effectiveness of conventional therapies, the increased use of ACE inhibitors and ARBs, the growing healthcare burden of renal failure, and the expansion of nephrology care services.
The kidney fibrosis treatment market size is projected for substantial expansion in the coming years. It is anticipated to reach $8.84 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 7.8%. This projected growth during the forecast period can be primarily ascribed to advancements in specific antifibrotic agents, an expanding elderly demographic afflicted with chronic kidney disease (CKD), the increasing integration of precision medicine within nephrology, heightened investment in renal research, and enhanced diagnosis of early-stage kidney disease. Key developments expected in this period encompass a heightened emphasis on developing antifibrotic drugs, a growing prevalence of combination therapies for CKD, increased research into stem cell and regenerative treatments, the expansion of tools for early diagnosis and monitoring, and an escalation in clinical trials focused on renal fibrosis pathways.
Get A Free Sample Report With In-Depth Market Insights:
Kidney Fibrosis Treatment Market Growth Drivers: What’s Behind The Acceleration?
The expanding prevalence of chronic kidney diseases is poised to drive the growth of the kidney fibrosis treatment market in the future. Chronic Kidney Disease (CKD) is characterized by a gradual deterioration of kidney function over time, often caused by underlying conditions such as diabetes or hypertension, leading to the accumulation of waste substances in the body. The escalation in CKD prevalence is largely attributable to the increasing rates of diabetes, which impairs kidney blood vessels and their filtering capabilities. Kidney fibrosis treatment offers assistance to CKD patients by targeting the scarring of renal tissue, mitigating inflammation, and decelerating the progression of kidney damage, ultimately preserving renal function. As an illustration, in July 2025, Hamadan University of Medical Sciences, an Iran-based university, projected that the global total of newly diagnosed chronic kidney diseases would climb to 25.06 million by 2030. Hence, the increasing prevalence of chronic kidney diseases is a key factor propelling the kidney fibrosis treatment market.
Kidney Fibrosis Treatment Market Segment Analysis: What Are The Core Market Categories?
The kidney fibrosis treatment market covered in this report is segmented –
1) By Treatment Type: Angiotensin-Converting Enzyme (Ace) Inhibitors, Angiotensin Ii Receptor Blockers (Arbs), Pirfenidone, Renin Inhibitors, Vasopeptidase Inhibitors, Other Treatment Types
2) By Diagnosis: Blood Tests, Urine Tests, Imaging Tests
3) By Application: Chronic Kidney Diseases, Kidney Cancer Treatment, Other Applications
4) By End-User: Clinics, Research Center, Hospitals
Subsegments:
1) By Angiotensin-Converting Enzyme (Ace) Inhibitors: Enalapril, Captopri, Lisinopril, Ramipril
2) By Angiotensin Ii Receptor Blockers (Arbs): Losartan, Telmisartan, Valsartan, Irbesartan
3) By Pirfenidone: Branded Pirfenidone, Generic Pirfenidone
4) By Renin Inhibitors: Aliskiren, Experimental Renin Inhibitors
5) By Vasopeptidase Inhibitors: Omapatrilat, Sampatrilat
6) By Other Treatment Types: Anti-Inflammatory Agents, Stem Cell Therapy, Antifibrotic Agents Under Clinical Trials, Gene Therapy
Kidney Fibrosis Treatment Market Trends: What’s Defining The Industry’s Next Phase?
Major companies in the kidney fibrosis treatment market are concentrating on targeted ileal-release immunomodulatory therapies, such as NEFECON. This oral delayed-release budesonide capsule is designed to deliver the drug specifically to the distal ileum, aiming to modulate gut-associated B-cells and reduce pathogenic IgA production, thereby slowing the progression of kidney fibrosis in IgA nephropathy patients. For instance, in June 2024, Everest Medicines, a biopharmaceutical company based in China, introduced NEFECON. The therapy features an enteric-coated, delayed-release formulation to minimize systemic steroid exposure, targets mucosal B-cells in the gut to address the core cause of IgA nephropathy, and has proven its ability to significantly reduce kidney function decline.
Kidney Fibrosis Treatment Market Top Companies Driving Competitive Growth
Major companies operating in the kidney fibrosis treatment market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, AstraZeneca PLC, Gilead Sciences Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Chinook Therapeutics Inc., Akebia Therapeutics Inc., Travere Therapeutics Inc., Reata Pharmaceuticals Inc., ProKidney LLC, Tvardi Therapeutics Inc., Alentis Therapeutics AG, Galecto Biotech AB, Vertex Pharmaceuticals Incorporated, Insilico Medicine Inc., Purespring Therapeutics Inc., La Jolla Pharmaceutical Company, Cara Therapeutics Inc
View The Full Kidney Fibrosis Treatment Market Report:
Kidney Fibrosis Treatment Market Regional Split: Which Areas Are Fueling Growth?
North America was the largest region in the kidney fibrosis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney fibrosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model